CRVS News & Analysis

Corvus (CRVS) Publishes Soquelitinib Study Data in Blood Journal

Corvus Pharmaceuticals (CRVS) announced the publication of data on soquelitinib in the journal Blood. This study provides insights into the drug's potential efficacy and safety profile. The publication marks a significant step for Corvus, as it seeks to advance its clinical research pipeline. This development highlights the company's commitment to addressing unmet medical needs in oncology, which may impact investor sentiment positively.